IntelGenx wins new US patent for bupropion hydrochloride
11.03.10
IntelGenx, a drug delivery company, has reported the US Patent and Trademark Office, or USPTO, issued patent number 7,674,479 for a key patent application protecting the company's CPI-300, a novel, high strength formulation of bupropion hydrochloride, the active ingredient in Wellbutrin XL.
The patent discloses the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix. The patent will ultimately provide broad protection for CPI-300 until 2027 and upon regulatory approval be listed in the FDA's Orange Book.
IntelGenx and Cary Pharmaceuticals have previously entered into a collaborative agreement to jointly develop and commercialize CPI-300 using IntelGenx's proprietary oral VersaTab delivery technology. Cary Pharmaceuticals serves as the new drug application for CPI-300.
Horst Zerbe, president and CEO of IntelGenx, said: "The successful issuance of this patent provides formidable intellectual property
Source: American Chronicle
How You–and Obama–Can Quit Smoking
01.03.10
Barack Obama’s doctor just told him he needs to quit smoking. It’s not the first time he’s heard it, and it probably won’t be the last–smokers have to quit multiple times before they’re finally done smoking. Here’s a quick run-down on what you and Obama can both do to increase the odds that the next time you quit will be the last time.
First, be ready to quit. Quitting is often a tough process, and there’s no point in starting if you know it won’t work. If you’re not ready to quit, figure out why not. Consider what you enjoy about smoking–an escape from the office, companionship, the comfort of a familiar habit. Start weighing those factors against what you don’t enjoy–the cost, the health effects, the holier-than-thou attitude from those yuppies in that Prius speeding by you.
Use these to play mindgames with yourself. Each time you light up, remember how bad it makes you smell. Or think what you could do instead with all the money you’ve spent in the past month on cigarettes. Or if you’re inclined to the macabre, follow the advice of one of my patients who quit a pack-a-day habit. He made a list of twenty diseases linked to smoking (see the end of the article) and mentally labeled each cigarette in the pack with the name of one disease as he smoked it. If you consistently link smoking to something negative, you’ll be more prepared to give up the habit.
Source: The Faster Times
IntelGenx receives US patent for Bupropion hydrochloride
12.03.10
IntelGenx Corp announced that the US Patent and Trademark Office (US PTO) issued patent number 7,674,479 on March 9, 2010 for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL.
The patent entitled "Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets" discloses the formulation of pharmaceutical tablets containing sustained-release granules of Bupropion HCl distributed in a sustained-release matrix. The patent will ultimately provide broad protection for CPI-300 until 2027 (twenty years from the filing date) and upon regulatory approval be listed in the US Food and Drug Administration's (FDA) Orange Book.
"The successful issuance of this patent provides formidable intellectual property protection for CPI-300 and further strengthens our competitive position in the substantial Bupropion market," said Dr Horst G Zerbe, president and chief executive
Source: pharmabiz.com
"The report says Gardner took Ritalin, Cylert, Zoloft, Paxil and Wellbutrin, Tegretol, Mellaril, Imipramine and Wellbutrin. The report also notes that